AR059426A1 - Derivados de piperidina antagonistas de receptores cxcr3, metodo de preparacion,composiciones farmaceuticas que los contienen y usos para tratar enfermedades mediadas por la activacion del receptor cxcr3. - Google Patents
Derivados de piperidina antagonistas de receptores cxcr3, metodo de preparacion,composiciones farmaceuticas que los contienen y usos para tratar enfermedades mediadas por la activacion del receptor cxcr3.Info
- Publication number
- AR059426A1 AR059426A1 ARP070100557A ARP070100557A AR059426A1 AR 059426 A1 AR059426 A1 AR 059426A1 AR P070100557 A ARP070100557 A AR P070100557A AR P070100557 A ARP070100557 A AR P070100557A AR 059426 A1 AR059426 A1 AR 059426A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- polyhalo
- amino
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), un N-oxido de dicho compuesto, una sal aceptable para uso farmacéutico de dicho compuesto, una forma estereoquímicamente isomera de dicho compuesto, o un solvato de dicho compuesto, donde: X representa N o CH; Y y Z representan, de manera independiente, C(=O) o CH2, siempre que por lo menos uno de Y y Z represente C(=O); R1 representa CH(R4)-arilo o CH(R4)-heteroarilo; R2 representa arilo2 o heteroarilo; R3 representa H, alquilcarbonilo C1-4, alquil C1-6 opcionalmente sustituido con alquiloxi C1-6, alquiltio C1-6, alquiloxicarbonilo C1-6 o arilo1; R4 representa H o alquilo C1-4; R5 y R6 representan, de manera independiente, H o alquilo C1-6 opcionalmente sustituido con hidroxilo; o R5 y R6 junto con el N al cual están unidos forman un heterociclo monocíclico seleccionado de piperidinilo, piperazinilo, morfolinilo, o tiomorfolinilo, donde cada uno de dichos anillos está opcionalmente sustituido con alquilo C1-4; R7 representa H o alquilo C1-4; arilo representa naftilo no sustituido; o fenilo o naftilo, donde cada uno de dichos fenilo o naftilo está sustituido con por lo menos un sustituyente, donde cada sustituyente se selecciona de manera independiente de halo, hidroxilo, alquilo alquiloxi C1-6, alquiloxicarbonilo C1-6, alquilcarboniloxi C1-6, alquiltio C1-6, polihalo-alquilo C1-6, polihalo-alquiloxi C1-6, ciano, nitro, carboxilo, HO-SO2-, alquilo C1-4-SO2-, R6R5N-C(=O)-, amino, mono- o di(alquilo C1-4)amino, alquilcarbonilamino C1-4, arilo1, arilo1-alquiloxi C1-4, arilo1oxi, o arilo1C(=O)-; arilo1 representa fenilo o fenilo sustituido con 1; 2 o 3 sustituyentes, donde cada sustituyente se selecciona de manera independiente de halo, hidroxilo, alquilo C1- 6, alquiloxi C1-6, alquiloxicarbonilo C1-6, alquilcarboniloxi C1-6, alquiltio C1-6, polihalo-alquilo C1-6, polihalo-alquiloxi C1-6, ciano, nitro, carboxilo, aminocarbonilo, mono- o di(alquilo C1-4)aminocarbonilo, amino, o mono- o di(alquilo C1- 4)amino; arilo2 representa fenilo o naftilo, donde cada uno de dichos anillos está opcionalmente sustituido con por lo menos un sustituyente, donde cada sustituyente se selecciona de manera independiente de halo, hidroxilo, alquilo C1-6, alquiloxi C1-6, alquiloxicarbonilo C1-6, alquilcarboniloxi C1-6, alquiltio C1-6, polihalo-alquilo C1-6, polihalo-alquiloxi C1-6, ciano, nitro, carboxilo, HO-SO2-, alquilo C1-4-SO2-, R6R5N-C(=O)-, amino, mono- o di(alquilo C1-4)amino, alquilcarbonilamino C1-4, arilo1, arilo1-alquiloxi C1-4, arilo1oxi, o arilo1C(=O)-; heteroarilo representa un heterociclo monocíclico seleccionado de pirrolinilo, imidazolinilo, pirazolinilo, furanilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, isoxazolilo, isotiazolilo, oxadiazolilo, triazolilo, tiadiazolilo, piridilo, piridazinilo, pirimidinilo, pirazinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo; o un heterociclo bicíclico seleccionado de indolilo, indolizinilo, isoindolilo, indolinilo, benzofuranilo, benzotienilo, indazolilo, bencimidazolilo, benztiazolilo, purinilo, quinolizinilo, quinolinilo, isoquinolinilo, cinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, naftiridinilo, pteridinilo, benzoxadiazolilo, benzoxazolilo, benztiazolilo, donde cada uno de dichos heterociclos monocíclicos o bicíclicos está opcionalmente sustituido con por lo menos un sustituyente, donde cada sustituyente se selecciona de manera independiente de halo, hidroxilo, alquilo C1-6, alquiloxi C1-6, alquiloxicarbonilo C1-6, alquilcarboniloxi C1-6, alquiltio C1-6, polihalo-alquilo C1-6, polihalo-alquiloxi C1-6, ciano, nitro, carboxilo, HO-SO2-, alquilo C1-4-SO2-, R6R5N-C(=O)-, amino, mono- o di(alquilo C1- 4)amino, o alquilcarbonilamino C1-4; siempre que cuando Y y Z representen independientemente C(=O), X represente CH, R3 represente hidrogeno, R4 represente hidrogeno, y R2 represente piridilo no sustituido o fenilo opcionalmente sustituido con un halo o con un alquiloxi C1-4, o con uno o dos alquilo C1-4, entonces arilo en la definicion de R1 no es fenilo sustituido con un halo o con uno o dos alquilo C1-4; y siempre que cuando Y y Z representen independientemente C(=O), X represente CH, R3 represente hidrogeno, y R2 represente piridilo no sustituido o fenilo opcionalmente sustituido con un halo o con un alquiloxi C1-4, o con uno o dos alquilo C1-4, entonces heteroarilo en la definicion de R1 no es tienilo no sustituido o piridilo no sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06101560 | 2006-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059426A1 true AR059426A1 (es) | 2008-04-09 |
Family
ID=35906933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100557A AR059426A1 (es) | 2006-02-10 | 2007-02-09 | Derivados de piperidina antagonistas de receptores cxcr3, metodo de preparacion,composiciones farmaceuticas que los contienen y usos para tratar enfermedades mediadas por la activacion del receptor cxcr3. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090030039A1 (es) |
| EP (1) | EP1984349A1 (es) |
| JP (1) | JP2009526014A (es) |
| KR (1) | KR20080108422A (es) |
| CN (1) | CN101379054A (es) |
| AR (1) | AR059426A1 (es) |
| AU (1) | AU2007213734A1 (es) |
| BR (1) | BRPI0707623A2 (es) |
| CA (1) | CA2635137A1 (es) |
| IL (1) | IL193294A0 (es) |
| NO (1) | NO20083857L (es) |
| RU (1) | RU2008136391A (es) |
| TW (1) | TW200806644A (es) |
| WO (1) | WO2007090826A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| US9045445B2 (en) | 2010-06-04 | 2015-06-02 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3125578A (en) * | 1962-05-17 | 1964-03-17 | xxviii | |
| WO1995011234A1 (en) * | 1993-10-22 | 1995-04-27 | Australian Nuclear Science & Technology Organisation | Radiolabelled ligands for muscarinic receptors |
| RU2004100839A (ru) * | 2001-07-02 | 2005-06-20 | Астразенека Аб (Se) | Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов |
-
2007
- 2007-02-06 BR BRPI0707623-1A patent/BRPI0707623A2/pt not_active Application Discontinuation
- 2007-02-06 CA CA002635137A patent/CA2635137A1/en not_active Abandoned
- 2007-02-06 JP JP2008553746A patent/JP2009526014A/ja not_active Withdrawn
- 2007-02-06 EP EP07704385A patent/EP1984349A1/en not_active Withdrawn
- 2007-02-06 CN CNA2007800047716A patent/CN101379054A/zh active Pending
- 2007-02-06 WO PCT/EP2007/051106 patent/WO2007090826A1/en active Application Filing
- 2007-02-06 RU RU2008136391/04A patent/RU2008136391A/ru not_active Application Discontinuation
- 2007-02-06 KR KR1020087019755A patent/KR20080108422A/ko not_active Application Discontinuation
- 2007-02-06 US US12/278,719 patent/US20090030039A1/en not_active Abandoned
- 2007-02-06 AU AU2007213734A patent/AU2007213734A1/en not_active Abandoned
- 2007-02-09 AR ARP070100557A patent/AR059426A1/es unknown
- 2007-02-09 TW TW096104681A patent/TW200806644A/zh unknown
-
2008
- 2008-08-07 IL IL193294A patent/IL193294A0/en unknown
- 2008-09-08 NO NO20083857A patent/NO20083857L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1984349A1 (en) | 2008-10-29 |
| CN101379054A (zh) | 2009-03-04 |
| JP2009526014A (ja) | 2009-07-16 |
| TW200806644A (en) | 2008-02-01 |
| BRPI0707623A2 (pt) | 2011-05-10 |
| WO2007090826A1 (en) | 2007-08-16 |
| AU2007213734A1 (en) | 2007-08-16 |
| RU2008136391A (ru) | 2010-03-20 |
| KR20080108422A (ko) | 2008-12-15 |
| IL193294A0 (en) | 2009-05-04 |
| NO20083857L (no) | 2008-10-28 |
| US20090030039A1 (en) | 2009-01-29 |
| CA2635137A1 (en) | 2007-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| AR084430A1 (es) | Di/tri-aza-espiro-alcanos c | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
| AR110026A1 (es) | Inhibidores de pde2 | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR057911A1 (es) | Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| AR050969A1 (es) | 5-heterociclil pirimidinas inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| RU2017118335A (ru) | Гетероциклическое производное, обладающее активирующей ampk активностью | |
| AR048521A1 (es) | Derivados sustituidos de diaza-espiro-(4.5)-decano y su uso como antagonistas de neuroquininas | |
| AR097900A1 (es) | Composiciones de herbicida-protector que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR059426A1 (es) | Derivados de piperidina antagonistas de receptores cxcr3, metodo de preparacion,composiciones farmaceuticas que los contienen y usos para tratar enfermedades mediadas por la activacion del receptor cxcr3. | |
| AR068111A1 (es) | Compuesto de pirazina y piperidina piperazinil sustituida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |